^
Association details:
Biomarker:LY9 expression
Cancer:Burkitt Lymphoma
Drug Class:T-lymphocyte cell therapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Abstract 3250: CD229-targeted CAR T cell therapy for the treatment of B cell lymphoma

Published date:
08/15/2020
Excerpt:
Expression analysis of 12 B cell lymphoma cell lines including...Burkitt lymphoma...revealed consistent expression of CD229 transcript...Coculture of CD229 CAR T cells with B cell lymphoma cell lines resulted in effective eradication of B cell lymphoma cells...two Burkitt lymphoma…at low effector-target ratios while control CAR T cells had no effect.
DOI:
10.1158/1538-7445.AM2020-3250